JUNS
Jupiter Neurosciences Inc (JUNS)
Healthcare • NASDAQ • $0.33-3.26%
- Symbol
- JUNS
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $0.33
- Daily Change
- -3.26%
- Market Cap
- $12.07M
- Trailing P/E
- N/A
- Forward P/E
- 5.55
- 52W High
- $3.33
- 52W Low
- $0.31
- Analyst Target
- N/A
- Dividend Yield
- N/A
- Beta
- N/A
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinical trial for the treatment of Parkinson's disease; JNS108, which is in Phase II clinical trial for the treatment of mild cognitive impairment/early Alzheimer's disease; JNS102, which is in Phase II clinical trial for the treatment of mucopolysaccharidosis type 1; and JNS107, which is in Phase II clinical trial for the treatment of mitochondrial encephalopathy, lactic acidosis, and stroke-like episo…
Company websiteResearch JUNS on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.